MinervaX appoints new chief development and financial officers
Jamila Louahed joins as CDO from GSK and Hans Henrik Chrois Christensen as CFO, strengthening leadership as the GBS vaccine advances toward pivotal trials.
See the latest news and media coverage for MinervaX. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage vaccine biotechnology company
minervax.comLast updated
In short: MinervaX appointed two executives as its maternal GBS vaccine advanced toward pivotal trials
Jamila Louahed joins as CDO from GSK and Hans Henrik Chrois Christensen as CFO, strengthening leadership as the GBS vaccine advances toward pivotal trials.
The prophylactic maternal vaccine aims to prevent Group B Strep infections in newborns and pregnant women, and the company positions itself as a fast-follower with a better vaccine.
New investors EQT Life Sciences and OrbiMed join existing backers, giving the company over €125 million in reserves to start a Phase III trial in 2024.
It includes 22M EUR equity co-led by Trill Impact Ventures and Pureos Bioventures and a 50M EUR EIB loan facility, supporting Phase 3 preparation.
Plans include phase 3 clinical development of novel GBS vaccine and an efficacy evaluation Plans include phase 3 clinical development of novel GBS vaccine and...
against the giant Pfizer to deliver the first vaccine against GBS infection in newborns The goal is to vaccinate mothers, who, in addition to immunizing themselves, also...
- On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors to accelerate development of its novel vaccine through...
Existing investors Novo Holdings, Repair Impact Fund, Sunstone Life Science Ventures and LF Investment also joined the round. The proceeds will be used to advance...
Track MinervaX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to MinervaX and other trending companies.